Stocktoria
Arcus Biosciences, Inc. RCUS
NYSE · stock · Pharmaceutical Preparations · website · IPO 2018-03-15
Arcus Biosciences, Inc. financials (annual)
Bars are annual figures from 2017 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $247.0M | $258.0M | $117.0M | $112.0M | $383.0M | $78.0M | $15.0M | $8.4M | $1.4M |
| R&D expense | $523.0M | $448.0M | $340.0M | $288.0M | $257.0M | $159.0M | $78.5M | $49.6M | $47.2M |
| Operating income | -$386.0M | -$330.0M | -$340.0M | -$280.0M | $54.0M | -$124.0M | -$88.7M | -$54.9M | -$53.4M |
| Income tax | $0 | $1.0M | $6.0M | $1.0M | $2.0M | — | — | — | — |
| Net income | -$353.0M | -$283.0M | -$307.0M | -$267.0M | $53.0M | -$123.0M | -$84.7M | -$49.6M | -$53.1M |
| EPS (diluted) | $-3.29 | $-3.14 | $-4.15 | $-3.71 | $0.71 | $-2.24 | $-1.93 | — | — |
| Operating cash flow | -$482.0M | -$170.0M | -$306.0M | $438.0M | -$256.0M | $111.0M | -$73.5M | -$43.0M | -$25.1M |
| Free cash flow | -$484.0M | -$176.0M | -$330.0M | $432.0M | -$282.0M | $108.0M | -$75.4M | -$46.7M | -$30.6M |
| Cash & equivalents | $222.0M | $150.0M | $127.0M | $206.0M | $148.0M | $173.4M | $57.9M | $71.1M | $98.4M |
| Total assets | $1.1B | $1.1B | $1.1B | $1.3B | $1.6B | $772.3M | $203.1M | $274.9M | $190.5M |
| Total liabilities | — | — | — | — | $750.4M | $270.0M | $39.3M | $40.0M | $36.6M |
| Shareholders' equity | $631.0M | $485.0M | $462.0M | $657.0M | $842.0M | $502.0M | $164.0M | $234.9M | -$72.3M |
Growth · year-over-year · Revenue CAGR 90.7%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -4.3% | +120.5% | +4.5% | -70.8% | +391.0% | +420.0% | +79.6% | +491.2% | — |
| Net income growth | — | — | — | -603.8% | — | — | — | — | — |
| EPS growth | — | — | — | -622.5% | — | — | — | — | — |
| Free cash flow growth | — | — | -176.4% | — | -361.1% | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.